Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension
Status:
Recruiting
Trial end date:
2024-06-24
Target enrollment:
Participant gender:
Summary
This study is designed to investigate whether sympathoinhibition with moxonidine could
provide added metabolic benefit compared to the second line therapy in the current
guidelines.